Impaired tumor necrosis factor-α secretion by CD4 T cells during respiratory syncytial virus bronchiolitis associated with recurrent wheeze.
Bronchiolitis, Viral
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
Cells, Cultured
Cytokines
/ metabolism
Female
Humans
Infant
Male
Respiratory Sounds
/ etiology
Respiratory Syncytial Virus Infections
/ complications
Respiratory Syncytial Viruses
/ isolation & purification
Tumor Necrosis Factor-alpha
/ metabolism
Tregs
recurrent wheeze
respiratory syncytial virus bronchiolitis
tumor necrosis factor
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
04
07
2019
revised:
06
11
2019
accepted:
07
12
2019
pubmed:
5
1
2020
medline:
15
12
2020
entrez:
5
1
2020
Statut:
ppublish
Résumé
Infants with severe respiratory syncytial virus (RSV) bronchiolitis have an increased risk of recurrent wheezing and asthma. We aimed to evaluate the relationships between regulatory T cell (Treg) percentage and cytokine production of in vitro-stimulated CD4+ T cells during acute bronchiolitis and the development of recurrent wheezing in the first 3 years of life. We obtained peripheral blood from 166 infants hospitalized with their first episode of RSV-confirmed bronchiolitis. Granzyme B (GZB) expression, and interleukin-10, interferon-γ, tumor necrosis factor-α (TNF-α), IL-4, and IL-5 production by in vitro anti-CD3/CD28- and anti-CD3/CD46-activated CD4+ T cells, and percentage of peripheral Treg (CD4+CD25 Sixty-seven percent (n = 111) of children had wheezing after their initial RSV infection, with 30% having recurrent wheezing. The percentage of peripheral Treg (CD4+CD25 We demonstrated lower TNF-α production by in vitro stimulated CD4+ T cells during severe RSV bronchiolitis in children that subsequently developed recurrent wheezing, compared with children with no subsequent wheeze. These findings support the role of CD4+ T cell immunity in the development of subsequent wheezing in these children.
Sections du résumé
BACKGROUND
Infants with severe respiratory syncytial virus (RSV) bronchiolitis have an increased risk of recurrent wheezing and asthma. We aimed to evaluate the relationships between regulatory T cell (Treg) percentage and cytokine production of in vitro-stimulated CD4+ T cells during acute bronchiolitis and the development of recurrent wheezing in the first 3 years of life.
METHODS
We obtained peripheral blood from 166 infants hospitalized with their first episode of RSV-confirmed bronchiolitis. Granzyme B (GZB) expression, and interleukin-10, interferon-γ, tumor necrosis factor-α (TNF-α), IL-4, and IL-5 production by in vitro anti-CD3/CD28- and anti-CD3/CD46-activated CD4+ T cells, and percentage of peripheral Treg (CD4+CD25
RESULTS
Sixty-seven percent (n = 111) of children had wheezing after their initial RSV infection, with 30% having recurrent wheezing. The percentage of peripheral Treg (CD4+CD25
CONCLUSIONS
We demonstrated lower TNF-α production by in vitro stimulated CD4+ T cells during severe RSV bronchiolitis in children that subsequently developed recurrent wheezing, compared with children with no subsequent wheeze. These findings support the role of CD4+ T cell immunity in the development of subsequent wheezing in these children.
Identifiants
pubmed: 31901157
doi: 10.1002/iid3.281
pmc: PMC7016853
doi:
Substances chimiques
Cytokines
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-39Subventions
Organisme : NHLBI NIH HHS
ID : U54 HL112303
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM099111
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI070489
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL092486
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000448
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI041592
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Informations de copyright
© 2019 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Pediatr Allergy Immunol. 2011 Feb;22(1 Pt 2):e87-94
pubmed: 20408969
Eur Cytokine Netw. 2005 Jan-Mar;16(1):35-40
pubmed: 15809204
Egypt J Immunol. 2008;15(2):153-60
pubmed: 20306698
Pediatr Infect Dis J. 2012 Jan;31(1):86-9
pubmed: 21829141
Blood. 2004 Nov 1;104(9):2840-8
pubmed: 15238416
Am J Dis Child. 1986 Jun;140(6):543-6
pubmed: 3706232
Nat Med. 2012 Oct;18(10):1525-30
pubmed: 22961107
J Immunol. 2005 Feb 15;174(4):1783-6
pubmed: 15699103
Pediatr Infect Dis J. 2009 Oct;28(10):867-73
pubmed: 19738511
Iran J Allergy Asthma Immunol. 2018 Aug 12;17(4):388-392
pubmed: 30537802
Clin Exp Immunol. 2005 Jun;140(3):540-6
pubmed: 15932517
Mucosal Immunol. 2012 Mar;5(2):161-72
pubmed: 22236998
Am J Respir Crit Care Med. 2018 Oct 15;198(8):1064-1073
pubmed: 29733679
J Infect Dis. 2013 Feb 15;207(4):564-73
pubmed: 23204162
J Immunol. 2011 Sep 15;187(6):3145-54
pubmed: 21844390
Clin Immunol. 2017 Jan;174:73-83
pubmed: 27847316
J Virol. 2013 Oct;87(20):10946-54
pubmed: 23926350
J Allergy Clin Immunol. 2008 Oct;122(4):726-733.e3
pubmed: 18760461
Pediatr Infect Dis J. 1999 Feb;18(2):115-22
pubmed: 10048682
J Immunol. 2010 Aug 15;185(4):2382-92
pubmed: 20639494
Allergy. 2003 Sep;58(9):878-84
pubmed: 12911416
Eur J Immunol. 2009 Nov;39(11):3097-109
pubmed: 19784949
J Leukoc Biol. 2013 Jun;93(6):933-42
pubmed: 23543769
Annu Rev Immunol. 2018 Apr 26;36:309-338
pubmed: 29677470
Am J Respir Crit Care Med. 2003 Sep 15;168(6):633-9
pubmed: 12773328
Virology. 2015 Nov;485:36-46
pubmed: 26196232
J Infect Dis. 2017 Apr 1;215(7):1049-1058
pubmed: 28199704
Nature. 2003 Jan 23;421(6921):388-92
pubmed: 12540904
Clin Microbiol Rev. 2017 Apr;30(2):481-502
pubmed: 28179378
Pediatr Res. 2008 Jun;63(6):650-5
pubmed: 18317234
Immunol Res. 2014 Aug;59(1-3):109-17
pubmed: 24838148
Mol Immunol. 2014 Mar;58(1):98-107
pubmed: 24321396
PLoS One. 2012;7(2):e32371
pubmed: 22393401
Am J Respir Crit Care Med. 2008 Jan 15;177(2):208-18
pubmed: 17962634
J Exp Med. 2005 Dec 5;202(11):1539-47
pubmed: 16314435
BMC Pediatr. 2004 Dec 17;4(1):25
pubmed: 15606912
J Infect Dis. 2004 Jun 1;189(11):2047-56
pubmed: 15143472
Clin Exp Immunol. 2004 Jul;137(1):146-50
pubmed: 15196255
J Immunol. 2001 Aug 1;167(3):1245-53
pubmed: 11466340
J Allergy Clin Immunol. 2012 Jul;130(1):91-100.e3
pubmed: 22444510
Am J Respir Crit Care Med. 2014 Apr 1;189(7):865-8
pubmed: 24684360
J Infect Dis. 2001 Aug 15;184(4):393-9
pubmed: 11471095
Thorax. 2010 Dec;65(12):1045-52
pubmed: 20581410
J Infect Dis. 2017 Nov 15;216(8):1027-1037
pubmed: 28962005
Medicine (Baltimore). 2015 Sep;94(39):e1512
pubmed: 26426613
Respir Res. 2009 Sep 25;10:85
pubmed: 19781072
Nat Med. 2011 Jul 24;17(8):975-82
pubmed: 21785433
Immunol Cell Biol. 2001 Apr;79(2):132-40
pubmed: 11264706
Immun Inflamm Dis. 2020 Mar;8(1):30-39
pubmed: 31901157
PLoS One. 2014 Jan 31;9(1):e87162
pubmed: 24498037